arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Citius Pharmaceuticals, Inc.

CTXR

$0.57 ▼ -0.03 (-5.09%) at close

15 Visible periods

24 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Citius Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $6.3M

Dividend Yield —

Revenue Growth None

Op. Margin —

ROIC -58.6% ↗

FCF / Share $-2.40 ↗

Trailing P/E —

Price / Book 0.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

15-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$90.00K

— 0.0% —

Net Income Profit after all expenses

$-39.74M

↓ -0.8% —

FCF / Share Free cash flow per share

$-2.40

↑ +42.8% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Financial Health ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Sep 30, 2022 10-K ↗	FY 2021 Sep 30, 2021 10-K ↗	FY 2020 Sep 30, 2020 10-K ↗	FY 2019 Sep 30, 2019 10-K ↗	FY 2018 Sep 30, 2018 10-K ↗	FY 2017 Sep 30, 2017 10-K ↗	FY 2016 Sep 30, 2016 10-K ↗	FY 2015 Sep 30, 2015 10-K ↗	FY 2014 Sep 30, 2013 10-K ↗	FY 2013 Sep 30, 2012 10-K ↗	FY 2012 Sep 30, 2011 10-K ↗	FY 2011 Sep 30, 2010 10-K ↗
Revenue Growth YoY (%)	—	—	—	0.0% Caution ↓ Caution Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-100%)	0.0% Caution ↓ Caution Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-100%)	0.0% Caution Caution Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-100%)	20.0% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+150%)	—	—	—	—	—	—	—	—
EPS Growth YoY (%)	43.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-7.2% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-2321.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	0.0% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	-0.8% Weak ↑ Weak Improving Year-over-year change in net income	-21.2% Weak ↑ Weak Improving Year-over-year change in net income	3.3% Caution ↑ Caution Improving Year-over-year change in net income	-45.9% Weak ↓ Weak Declining Year-over-year change in net income	-31.4% Weak ↓ Weak Declining Year-over-year change in net income	-12.8% Weak ↑ Weak Improving Year-over-year change in net income	-24.1% Weak ↑ Weak Improving Year-over-year change in net income	-20.7% Weak ↑ Weak Improving Year-over-year change in net income	-25.2% Weak ↑ Weak Improving Year-over-year change in net income	-1024.5% Weak ↓ Weak Declining Year-over-year change in net income	-674.8% Weak ↓ Weak Declining Year-over-year change in net income	-332.7% Weak ↓ Weak Declining Year-over-year change in net income	16.5% Good Good Year-over-year change in net income	-69.9% Weak Weak Year-over-year change in net income	—
FCF Growth YoY (%)	42.8% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	12.7% Fair ↑ Fair Improving Year-over-year change in free cash flow	-2373.4% Weak Weak Year-over-year change in free cash flow	13.1% Fair Fair Year-over-year change in free cash flow	—	—	—	—	—	—	—	-279.9% Weak Weak Year-over-year change in free cash flow	2.2% Caution Caution Year-over-year change in free cash flow	—	—
Revenue CAGR 3Y (%)	—	—	—	0.0% Weak Weak Compound annual revenue growth over 3 years	6.3% Fair Fair Compound annual revenue growth over 3 years	—	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Sep 30, 2022 10-K ↗	FY 2021 Sep 30, 2021 10-K ↗	FY 2020 Sep 30, 2020 10-K ↗	FY 2019 Sep 30, 2019 10-K ↗	FY 2018 Sep 30, 2018 10-K ↗	FY 2017 Sep 30, 2017 10-K ↗	FY 2016 Sep 30, 2016 10-K ↗	FY 2015 Sep 30, 2015 10-K ↗	FY 2014 Sep 30, 2013 10-K ↗	FY 2013 Sep 30, 2012 10-K ↗	FY 2012 Sep 30, 2011 10-K ↗	FY 2011 Sep 30, 2010 10-K ↗
Effective Tax Rate (%) (%)	-2.7% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.5% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.8% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.7% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—	—	—	—	—	—	—
FCF / Net Income (x)	0.67x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.05x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.71x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.25x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.79x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Sep 30, 2022 10-K ↗	FY 2021 Sep 30, 2021 10-K ↗	FY 2020 Sep 30, 2020 10-K ↗	FY 2019 Sep 30, 2019 10-K ↗	FY 2018 Sep 30, 2018 10-K ↗	FY 2017 Sep 30, 2017 10-K ↗	FY 2016 Sep 30, 2016 10-K ↗	FY 2015 Sep 30, 2015 10-K ↗	FY 2014 Sep 30, 2013 10-K ↗	FY 2013 Sep 30, 2012 10-K ↗	FY 2012 Sep 30, 2011 10-K ↗	FY 2011 Sep 30, 2010 10-K ↗
Return on Invested Capital (%)	-58.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-60.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-41.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-33.0% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-14.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-41.6% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-45.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-39.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-35.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-35.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	69.6% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	477.8% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	33.8% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	85.0% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-29.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-36.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-35.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-29.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-16.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-40.5% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-42.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-44.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-40.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-33.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-88.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	—	-14531.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-12092.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-58.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-492%)	-56.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-475%)	-35.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-339%)	-32.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-318%)	-17.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-216%)	-52.1% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-447%)	-57.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-482%)	-45.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-400%)	-47.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-415%)	-49.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-430%)	99.4% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+563%)	—	48.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+220%)	110.5% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+637%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Sep 30, 2022 10-K ↗	FY 2021 Sep 30, 2021 10-K ↗	FY 2020 Sep 30, 2020 10-K ↗	FY 2019 Sep 30, 2019 10-K ↗	FY 2018 Sep 30, 2018 10-K ↗	FY 2017 Sep 30, 2017 10-K ↗	FY 2016 Sep 30, 2016 10-K ↗	FY 2015 Sep 30, 2015 10-K ↗	FY 2014 Sep 30, 2013 10-K ↗	FY 2013 Sep 30, 2012 10-K ↗	FY 2012 Sep 30, 2011 10-K ↗	FY 2011 Sep 30, 2010 10-K ↗
Interest Coverage (x)	-774.38x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	-2171.04x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-1130.01x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-948.63x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-870.64x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-11.74x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-828.25x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-7.03x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-14.01x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-8.22x Weak Weak Operating income divided by interest expense Optimal: > 5x	-36.42x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-4.25M	$-3.25M	$-26.48M	$-41.71M	$-70.07M	$-13.86M	$-7.89M	$-9.18M	$-3.20M	$-1.63M	$-1.55M	$0.00	$-135.00	$-212.00	$-2.50K

📊 What does each share earn? 6 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Sep 30, 2022 10-K ↗	FY 2021 Sep 30, 2021 10-K ↗	FY 2020 Sep 30, 2020 10-K ↗	FY 2019 Sep 30, 2019 10-K ↗	FY 2018 Sep 30, 2018 10-K ↗	FY 2017 Sep 30, 2017 10-K ↗	FY 2016 Sep 30, 2016 10-K ↗	FY 2015 Sep 30, 2015 10-K ↗	FY 2014 Sep 30, 2013 10-K ↗	FY 2013 Sep 30, 2012 10-K ↗	FY 2012 Sep 30, 2011 10-K ↗	FY 2011 Sep 30, 2010 10-K ↗
Revenue per Share (USD)	—	—	—	$0.00	$0.00	—	—	—	—	—	—	$0.00	$0.00	$0.00	—
Basic EPS, GAAP (USD)	$-3.38	$-5.97	$-5.57	$-0.23	$-0.23	—	—	—	—	—	—	$0.00	$0.00	$0.00	—
Free Cash Flow per Share (USD)	$-2.40	$-4.19	$-4.80	$-0.19	$-0.22	—	—	—	—	—	—	$-0.00	$-0.00	$-0.00	—
Book Value per Share (USD)	$3.74	$9.67	$14.29	$0.70	$0.91	$0.61	$0.94	$1.72	$2.63	$3.44	$-0.02	$-0.00	$-0.00	$-0.00	$0.00
Tangible Book Value per Share (USD)	$3.22	$8.38	$12.82	$0.64	$0.84	$0.44	$0.62	$1.62	$2.44	$3.11	$-0.02	$-0.00	$-0.00	$-0.00	$0.00
Basic Weighted Avg Shares (shares)	11.07M	6.73M	6.05M	146.08M	108.60M	—	—	—	—	—	—	18.00M	18.00M	18.00M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Sep 30, 2022 10-K ↗	FY 2021 Sep 30, 2021 10-K ↗	FY 2020 Sep 30, 2020 10-K ↗	FY 2019 Sep 30, 2019 10-K ↗	FY 2018 Sep 30, 2018 10-K ↗	FY 2017 Sep 30, 2017 10-K ↗	FY 2016 Sep 30, 2016 10-K ↗	FY 2015 Sep 30, 2015 10-K ↗	FY 2014 Sep 30, 2013 10-K ↗	FY 2013 Sep 30, 2012 10-K ↗	FY 2012 Sep 30, 2011 10-K ↗	FY 2011 Sep 30, 2010 10-K ↗
Working Capital (USD)	$-16.98M	$-21.59M	$28.59M	$40.03M	$68.83M	$9.88M	$3.33M	$6.88M	$955.19K	$-4.29M	$-640.61K	$-14.69K	$-45.85K	$-23.84K	—
Total Equity (USD)	$67.55M	$70.08M	$90.83M	$102.83M	$132.18M	$33.67M	$27.15M	$27.87M	$21.95M	$16.77M	$-741.93K	$-14.69K	$-45.85K	$-23.84K	$2.50K

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Sep 30, 2022 10-K ↗	FY 2021 Sep 30, 2021 10-K ↗	FY 2020 Sep 30, 2020 10-K ↗	FY 2019 Sep 30, 2019 10-K ↗	FY 2018 Sep 30, 2018 10-K ↗	FY 2017 Sep 30, 2017 10-K ↗	FY 2016 Sep 30, 2016 10-K ↗	FY 2015 Sep 30, 2015 10-K ↗	FY 2014 Sep 30, 2013 10-K ↗	FY 2013 Sep 30, 2012 10-K ↗	FY 2012 Sep 30, 2011 10-K ↗	FY 2011 Sep 30, 2010 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	$90.00K	$90.00K	$90.00K	$90.00K	$75.00K	—	—	—	$0.00	$0.00	$0.00	—
Depreciation Expense (USD)	—	$1.43K	$2.67K	$2.92K	$1.49K	$844.00	$893.00	$1.75K	$2.63K	$1.34K	—	—	—	—	—
Net Income, GAAP (USD)	$-39.74M	$-39.43M	$-32.54M	$-33.64M	$-23.05M	$-17.55M	$-15.56M	$-12.54M	$-10.38M	$-8.30M	$-737.73K	$-95.22K	$-22.01K	$-26.34K	$-15.50K
Operating Cash Flow (USD)	$-26.55M	$-28.20M	$-29.06M	$-28.36M	$-24.25M	$-16.93M	$-12.44M	$-11.32M	$-7.97M	$-5.90M	$-183.16K	$-77.21K	$-20.32K	$-20.78K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 15 years · 63 quarters

Citius Pharmaceuticals, Inc.

Analytical Summary

15-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CTXR with peers